自動・閉鎖型細胞治療システム市場：ワークフロー、タイプ、規模別-2025-2030年の世界予測

自動・閉鎖型細胞治療システム市場は、2023年に9億4,394万米ドルと評価され、2024年には10億8,797万米ドルに達すると予測され、CAGR 15.74％で成長し、2030年には26億2,676万米ドルになると予測されています。

自動・閉鎖型細胞治療システムは、幹細胞治療や遺伝子治療などの治療法の製造とスケーリングに焦点を当てた、現代の再生医療に不可欠なコンポーネントです。これらのシステムは、再現可能で安全な無菌の製造プロセスを可能にし、細胞治療製品の一貫性と規制遵守を保証します。その必要性は、複雑な疾患に対する効果的な細胞ベースの治療に対する需要が急増していることに起因しており、スケーラブルで効率的、かつ費用対効果の高い生産ソリューションが求められています。アプリケーションは、製薬・バイオテクノロジー部門、学術研究、臨床研究所に及んでいます。これらのシステムは、CAR-T細胞、幹細胞、および再生医療で使用されるその他の細胞製品の生産において極めて重要であり、がん、遺伝性疾患、および変性疾患の治療において最終的な利点を提供します。

市場成長の主な原動力は、細胞治療技術の進歩、研究資金の増加、再生医療に対する認識と導入の高まりです。主な成長要因としては、バイオプロセスにおける技術革新、臨床試験活動の増加、バイオテクノロジー企業と研究機関の戦略的提携などが挙げられます。ビジネスチャンスは、コスト効率を高めるためにこれらのシステムを最適化し、リアルタイムのモニタリングとAI主導の品質管理を提供する統合プラットフォームを開発することにあります。企業は、新たな市場の可能性を活用するために、自動化技術の強化、ユーザーインターフェースの簡素化、規制遵守の徹底に注力すべきです。

システム導入の高コスト、厳しい規制状況、技術的な複雑さなどの課題は、成長を阻害する可能性があります。さらに、熟練した人材の不足や、進化する治療技術に対応した継続的なアップデートの必要性もハードルとなっています。こうした課題を克服するために、企業は研修プログラムに投資し、イノベーションのために学術機関と協力すべきです。技術革新と研究が適している分野には、モジュール式システム設計の進歩、治療用の新しい細胞タイプの探求、プロセス制御強化のためのIoT統合などがあります。市場はダイナミックであり、急速な進歩と競合によるプレッシャーを特徴としているため、世界的に急増する細胞治療の需要を効率的に活用するためには、継続的なイノベーションと戦略的ポジショニングが必要です。

市場力学：急速に進化する自動・閉鎖型細胞治療システム市場の主要市場インサイトを公開

自動・閉鎖型細胞治療システム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 再生医療と細胞治療の人気の高まり
  • 費用対効果が高く、個別化された医薬品へのニーズの高まり
  • 自動化システムの手動処理に対する運用上の優位性
• 市場抑制要因
  • 治療法の違いによる生物学的変異
• 市場機会
  • 自動細胞治療処理システムの研究開発の進展
  • 高度な治療開発手順とソフトウェア技術の統合
• 市場の課題
  • 熟練した専門家の不足と自動化の複雑なプロセス

ポーターのファイブフォース：自動・閉鎖型細胞治療システム市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：自動・閉鎖型細胞治療システム市場における外部からの影響の把握

外部マクロ環境要因は、自動・閉鎖型細胞治療システム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析自動・閉鎖型細胞治療システム市場における競合情勢の把握

自動・閉鎖型細胞治療システム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス自動・閉鎖型細胞治療システム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、自動・閉鎖型細胞治療システム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨自動・閉鎖型細胞治療システム市場における成功への道筋を描く

自動・閉鎖型細胞治療システム市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 再生医療と細胞療法の人気の高まり
    • コスト効率の高い個別化医薬品へのニーズの高まり
    • 手動処理に対する自動化システムの運用上の優位性
  • 抑制要因
    • 異なる治療法に関連する生物学的変異
  • 機会
    • 自動細胞治療処理システムの研究開発活動の推進
    • 先進的な治療開発手順とソフトウェア技術の統合
  • 課題
    • 熟練した専門家の不足と自動化の複雑なプロセス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 自動・閉鎖型細胞治療システム市場：ワークフロー別

• アフェレーシス
• 凍結保存
• 拡大
• 充填-仕上げ
• 分離

第7章 自動・閉鎖型細胞治療システム市場：タイプ別

• 非幹細胞療法
• 幹細胞療法

第8章 自動・閉鎖型細胞治療システム市場スケール別

• 商業規模
• プレコマーシャルまたはR&Dスケール

第9章 南北アメリカの自動・閉鎖型細胞治療システム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の自動・閉鎖型細胞治療システム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの自動・閉鎖型細胞治療システム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Bio-Techne Corporation
• BioLife Solutions Inc.
• BioSpherix, Ltd.
• Cellares Inc.
• Corning Incorporated
• Cytiva
• Danaher Corporation
• Fresenius SE & Co. KGaA
• General Electric Company
• Lonza Group AG
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• Novartis AG
• Pluristem Therapeutics Inc.
• Regeneus Ltd.
• Sartorius AG
• STEMCELL Technologies Canada Inc.
• Terumo Corporation
• Thermo Fisher Scientific, Inc.
• Thermogenesis Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET RESEARCH PROCESS
• FIGURE 2. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET DYNAMICS
• TABLE 7. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APHERESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY EXPANSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILL- FINISH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SEPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRE-COMMERCIAL OR R&D SCALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 30. CANADA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 47. CHINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 50. INDIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 102. ITALY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 114. POLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 117. QATAR AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SCALE, 2018-2030 (USD MILLION)
• TABLE 146. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

The Automated & Closed Cell Therapy Processing Systems Market was valued at USD 943.94 million in 2023, expected to reach USD 1,087.97 million in 2024, and is projected to grow at a CAGR of 15.74%, to USD 2,626.76 million by 2030.

Automated & Closed Cell Therapy Processing Systems are essential components of modern regenerative medicine, focusing on the manufacture and scaling of therapies such as stem cell treatments and gene therapies. These systems enable reproducible, safe, and sterile production processes, ensuring consistency and regulatory compliance in cell therapy products. Their necessity stems from the burgeoning demand for effective cell-based treatments for complex diseases, requiring scalable, efficient, and cost-effective production solutions. Applications span the pharmaceutical and biotechnology sectors, academic research, and clinical laboratories. These systems are pivotal in producing CAR-T cells, stem cells, and other cellular products used in regenerative medicine, offering end-use benefits in treating cancers, genetic disorders, and degenerative diseases.

Market growth is primarily driven by advancements in cell therapy technologies, increasing research funding, and heightened awareness and adoption of regenerative medicine. The key growth factors include technological innovations in bioprocessing, increasing clinical trial activities, and strategic collaborations between biotech firms and research institutions. Opportunities lie in optimizing these systems for cost-efficiency and developing integrated platforms offering real-time monitoring and AI-driven quality control. Companies should focus on enhancing automation technologies, simplifying user interfaces, and ensuring regulatory compliance to capitalize on emerging market possibilities.

Challenges such as the high cost of system implementation, stringent regulatory landscapes, and technical complexities can impede growth. Moreover, skilled personnel shortages and the need for continuous updates in response to evolving therapeutic technologies also pose hurdles. To overcome these challenges, businesses should invest in training programs and collaborate with academic institutions for innovation. Areas ripe for innovation and research include advancing modular system designs, exploring new cell types for therapy, and integrating IoT for enhanced process control. The market is dynamic, characterized by rapid advancements and competitive pressures, necessitating continuous innovation and strategic positioning to leverage the burgeoning demand for cell therapies globally efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Automated & Closed Cell Therapy Processing Systems Market

The Automated & Closed Cell Therapy Processing Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising popularity of regenerative medicines & cell therapies
  • Growing need for cost-effective and personalized drugs
  • Operational superiority of automated systems over manual processing
• Market Restraints
  • Biological variations associated with different therapies
• Market Opportunities
  • Advancing research and development activities in automated cell therapy processing systems
  • Integration of advanced therapy development procedures and software technologies
• Market Challenges
  • Lack of skilled professionals and complicated process of automation

Porter's Five Forces: A Strategic Tool for Navigating the Automated & Closed Cell Therapy Processing Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Automated & Closed Cell Therapy Processing Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Automated & Closed Cell Therapy Processing Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Automated & Closed Cell Therapy Processing Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Automated & Closed Cell Therapy Processing Systems Market

A detailed market share analysis in the Automated & Closed Cell Therapy Processing Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Automated & Closed Cell Therapy Processing Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Automated & Closed Cell Therapy Processing Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Automated & Closed Cell Therapy Processing Systems Market

A strategic analysis of the Automated & Closed Cell Therapy Processing Systems Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Automated & Closed Cell Therapy Processing Systems Market, highlighting leading vendors and their innovative profiles. These include Bio-Techne Corporation, BioLife Solutions Inc., BioSpherix, Ltd., Cellares Inc., Corning Incorporated, Cytiva, Danaher Corporation, Fresenius SE & Co. KGaA, General Electric Company, Lonza Group AG, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novartis AG, Pluristem Therapeutics Inc., Regeneus Ltd., Sartorius AG, STEMCELL Technologies Canada Inc., Terumo Corporation, Thermo Fisher Scientific, Inc., and Thermogenesis Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Automated & Closed Cell Therapy Processing Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Workflow, market is studied across Apheresis, Cryopreservation, Expansion, Fill- Finish, and Separation.
• Based on Type, market is studied across Non-Stem Cell Therapy and Stem Cell Therapy.
• Based on Scale, market is studied across Commercial Scale and Pre-commercial or R&D Scale.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising popularity of regenerative medicines & cell therapies
    • 5.1.1.2. Growing need for cost-effective and personalized drugs
    • 5.1.1.3. Operational superiority of automated systems over manual processing
  • 5.1.2. Restraints
    • 5.1.2.1. Biological variations associated with different therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancing research and development activities in automated cell therapy processing systems
    • 5.1.3.2. Integration of advanced therapy development procedures and software technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of skilled professionals and complicated process of automation
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Automated & Closed Cell Therapy Processing Systems Market, by Workflow

• 6.1. Introduction
• 6.2. Apheresis
• 6.3. Cryopreservation
• 6.4. Expansion
• 6.5. Fill- Finish
• 6.6. Separation

7. Automated & Closed Cell Therapy Processing Systems Market, by Type

• 7.1. Introduction
• 7.2. Non-Stem Cell Therapy
• 7.3. Stem Cell Therapy

8. Automated & Closed Cell Therapy Processing Systems Market, by Scale

• 8.1. Introduction
• 8.2. Commercial Scale
• 8.3. Pre-commercial or R&D Scale

9. Americas Automated & Closed Cell Therapy Processing Systems Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Automated & Closed Cell Therapy Processing Systems Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Automated & Closed Cell Therapy Processing Systems Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bio-Techne Corporation
• 2. BioLife Solutions Inc.
• 3. BioSpherix, Ltd.
• 4. Cellares Inc.
• 5. Corning Incorporated
• 6. Cytiva
• 7. Danaher Corporation
• 8. Fresenius SE & Co. KGaA
• 9. General Electric Company
• 10. Lonza Group AG
• 11. Merck KGaA
• 12. Miltenyi Biotec B.V. & Co. KG
• 13. Novartis AG
• 14. Pluristem Therapeutics Inc.
• 15. Regeneus Ltd.
• 16. Sartorius AG
• 17. STEMCELL Technologies Canada Inc.
• 18. Terumo Corporation
• 19. Thermo Fisher Scientific, Inc.
• 20. Thermogenesis Holdings, Inc.